Raymond James Begins Coverage on Veru (NASDAQ:VERU)

Analysts at Raymond James assumed coverage on shares of Veru (NASDAQ:VERU) in a note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $3.00 price target on the stock. Raymond James’ price objective would indicate a potential upside of 363.97% from the stock’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Veru in a research note on Thursday, February 8th.

Veru Stock Up 6.0 %

Shares of VERU opened at $0.65 on Thursday. Veru has a 12-month low of $0.36 and a 12-month high of $1.52. The firm has a market capitalization of $88.99 million, a PE ratio of -0.57 and a beta of -0.23. The stock’s fifty day simple moving average is $0.53 and its 200-day simple moving average is $0.73.

Institutional Investors Weigh In On Veru

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VERU. Segment Wealth Management LLC increased its holdings in shares of Veru by 50.0% in the third quarter. Segment Wealth Management LLC now owns 60,000 shares of the company’s stock worth $43,000 after acquiring an additional 20,000 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Veru by 28.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 52,671 shares of the company’s stock worth $62,000 after acquiring an additional 11,810 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Veru by 41.5% in the first quarter. Deutsche Bank AG now owns 43,396 shares of the company’s stock worth $50,000 after acquiring an additional 12,729 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Veru in the fourth quarter worth about $32,000. Finally, XTX Topco Ltd bought a new stake in shares of Veru in the second quarter worth about $32,000. Institutional investors own 47.16% of the company’s stock.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.